Oral Contraceptives with Drospirenone improve PMS symptoms among women

Premenstrual syndrome (PMS) affects a significant number of women, and for those with the more severe form, premenstrual dysphoric disorder (PMDD), finding effective treatment options is crucial. In a recent study published in Cochrane Database of Systematic Reviews, researchers examined the effectiveness and safety of combined oral contraceptives (COCs) containing drospirenone in treating PMS and PMDD symptoms.

The study included analysis of five randomized controlled trials involving 858 women diagnosed with PMDD, found that COCs containing drospirenone and ethinylestradiol (EE) showed potential for improving overall premenstrual symptoms and functional impairments associated with PMS.

The key findings of the study:

COCs containing drospirenone and EE were associated with a reduction in overall premenstrual symptoms and functional impairment in terms of productivity, social activities, and relationships. However, it is important to note that the effects observed were considered small to moderate.

While the study showed positive effects on symptom improvement, it also indicated a higher likelihood of adverse effects and withdrawal from trials compared to the placebo groups.

Adverse effects reported included increased breast pain, nausea, intermenstrual bleeding, and menstrual disorders. However, no rare but serious adverse effects such as venous thromboembolism were reported.

The researchers emphasized that further investigation is required to determine the long-term effectiveness of COCs containing drospirenone and EE, whether they are beneficial for women with less severe symptoms, and how they compare to other combined oral contraceptives containing different progestogens.

These findings provide valuable insights into the potential benefits and considerations associated with using COCs containing drospirenone in the management of PMS and PMDD symptoms. It is important for women to consult with their healthcare providers to discuss the suitability of this treatment option based on their individual circumstances and medical history.

As research in this area continues, the aim is to develop safe and effective treatments that can significantly improve the quality of life for women living with PMS and PMDD. Future studies may further explore the optimal dosage and duration of treatment, as well as compare the efficacy of COCs containing drospirenone with other available options.

Source:

Ma, S., & Song, S. J. (2023). Oral contraceptives containing drospirenone for premenstrual syndrome. In Cochrane Database of Systematic Reviews (Vol. 2023, Issue 6). Wiley. https://doi.org/10.1002/14651858.cd006586.pub5